Table 2.
In vivo immunoadjuvant potency of PCEP
| Pathogen | Antigen | Animal Model | ROA | Comparison adjuvants | REF |
|---|---|---|---|---|---|
| Viral antigens | |||||
| Influenza | X-31, A/Aichi/68 (H3:N2) | mice | IN, SC, ORAL | PCPP | [29, 37, 39, 89] |
| HBV | HBsAg, recombinant | mice | SC | PCPP, CpG | [30, 39] |
| HCV | E2, envelope glycoprotein | mice | IP | Alum, Addavax, PCPP | [10] |
| IBHV | Recombinant or native hexon protein, inactivate virus | chicken | IM, in ovo | avian beta defensin 2, combination | [90, 91] |
| SwIV | H1N1, Inactivated | pigs | ID, IM | Emulsigen | [92, 93] |
| Bacterial antigens | |||||
| Bordetella pertussis | PTd | mice | SC | CpG, IDR, PCPP | [56, 94] |
| Actinobacillus pleuropneum oniae | OmlA | pigs | SC | CpG, Emulsigen | [86] |
| Model antigens | |||||
| BSA | mice | SC | Alum, PCPP | [29] | |
| Ovalbumin | mice | SC, IN | PCPP, CpG, Ca-PCPP, poly I:C, c-di-AMP, IDR, combinations | [58, 61] | |
(ROA-route of administration; REF-references; SC-subcutaneous; IM-intramuscular; ID-intradermal; IN-intranasal; IP-intraperitoneal; HBV-hepatitis B virus; HBsAg-hepatitis B Surface antigen; HCV-hepatitis C virus; IBHV-inclusion body hepatitis virus; SwIV-swine influenza virus; Ptd-pertussis toxoid; OmIA-outer membrane antigen; BSA-bovine serum albumin; CpG-CpG oligodeoxynucleotide; c-di-AMP-bis-(3′,5′)-cyclic dimeric adenosine monophosphate; IDR-cationic innate defense regulator peptides, Ca-PCPP-calcium cross-linked PCPP, poly I:C-polyinosinic:polycytidylic acid)